Wendy Stock to Cyclin-Dependent Kinase Inhibitor p15
This is a "connection" page, showing publications Wendy Stock has written about Cyclin-Dependent Kinase Inhibitor p15.
Connection Strength
0.152
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
Score: 0.112
-
Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71.
Score: 0.040